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M A J O R A R T I C L E
Mefloquine Is Highly Efficacious against
Chloroquine-Resistant Plasmodium vivax Malaria
and Plasmodium falciparum Malaria in Papua,
Indonesia
Jason D. Maguire,1,a Krisin,1 Hariyani Marwoto,2 Thomas L. Richie,4 David J. Fryauff,3 and J. Kevin Baird1
1US Naval Medical Research Unit No. 2 and 2National Institute of Health Research and Development, Jakarta, Indonesia; 3US Naval Medical
Research Unit No. 3, Cairo, Egypt; and 4Naval Medical Research Center, Silver Spring, Maryland
(See the editorial commentary by Vinetz on pages 1073–4)
Background. During the period of 1996–1999, we prospectively monitored 243 Javanese adults and children
after arriving in Papua, Indonesia, and microscopically documented each new case of malaria by active surveillance.
Methods. In a randomized, open-label, comparative malaria treatment trial, 72 adults and 50 children received
chloroquine for each incident case of malaria, and 74 adults and 47 children received mefloquine.
Results. Among 975 primary treatment courses, the cumulative 28-day curative efficacies were 26% and 82%
for chloroquine against Plasmodium falciparum malaria and Plasmodium vivax malaria, respectively. Mefloquine
cure rates were far superior (96% against P. falciparum malaria and 99.6% against P. vivax malaria).
Conclusions. Mefloquine is a useful alternative treatment for P. vivax malaria and P. falciparum malaria in
areas such as Papua, where chloroquine is still recommended as the first-line therapeutic agent.
The US Food and Drug Administration approves the
use of mefloquine for treatment of mild-to-moderate
acute malaria caused by mefloquine-susceptible strains
of Plasmodium falciparum or by Plasmodium vivax [1].
However, published data supporting the use of meflo-
quine for P. vivax malaria is limited to treatment out-
comes from 85 courses of therapy [2–6]. These data
are also limited to settings where the comparator agent
was chloroquine, for which clinical susceptibility has
been confirmed. Assertions of mefloquine-resistant P.
vivax have been described in only 3 case reports [7–9].
We evaluated the efficacy of mefloquine versus chlo-
roquine, the approved first-line agent for treatment of
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malaria in Indonesia, against P. falciparum and P. vivax
malaria in Indonesian Papua, where chloroquine resis-
tance occurs and where historical treatment failure rates
range from 54% to 80% for P. falciparum malaria and
from 22% to 70% for P. vivax malaria [10–12].
SUBJECTS AND METHODS
We prospectively monitored a cohort of Javanese mi-
grants starting immediately after their arrival to a ma-
laria-endemic coastal settlement village 150 km west of
the Papua provincial capital in eastern Indonesia. The
study location and population are described in detail
elsewhere [13]. In brief, this malaria-naive population
arrived from Java between August and October 1996,
during which period 243 migrants enrolled in a pro-
spective study of the onset of naturally acquired im-
munity [14]. In this block-randomized, open-label
comparative treatment trial, 72 adults (age, 20 years)
and 50 children (age, 6–12 years) were randomized to
receive chloroquine for each incident primary case of
uncomplicated malaria, and 74 adults and 47 children
were randomized to receive mefloquine. Only individ-
uals with normal glucose-6-phosphate dehydrogenase
activity (as determined using the G-6-PDH Screening
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Chloroquine Mefloquine Chloroquine Mefloquine
No. of subjects 50 47 72 74
No. of male/female subjects 32/18 31/16 47/25 53/21
Age, mean years (range) 9.1 (6–12) 9.3 (6–12) 31.9 (20–58) 31.7 (20–50)
Weight, mean kg (range) 22.6 (15.4–38.2) 22.8 (13–34.7) 51.1 (35.5–64) 52.1 (37.8–83.3)
Test 203-A [Sigma Diagnostics]) participated in the study. From
November 1996 to June 1999, native language–speaking study
personnel visited subjects thrice weekly and obtained blood
smear specimens during any visit in which a subject complained
of having fever, rigors, nausea/vomiting, headache, or malaise
significant enough to interfere with work or school activities.
Technicians also prepared routine blood smears for all study
subjects every 2 weeks, regardless of symptoms.
Each incident case of slide-proven uncomplicated malaria
was treated according to the protocol for the group to which
the subject had been assigned during randomization. Subjects
in the chloroquine arm received chloroquine diphosphate (150-
mg base; Resochin [P. T. Bayer Indonesia]) in 3 doses over 48
h: 10 mg base/kg on day 0, 10 mg base/kg on day 1, and 5 mg
base/kg on day 2. Subjects assigned to the mefloquine arm
received mefloquine hydrochloride (228-mg base; Lariam
[Roche]) as a single 15-mg/kg dose. Subjects with P. vivax
malaria also received primaquine phosphate (15 mg base daily
for 14 days). Native language–speaking study personnel ob-
served administration of all treatment doses and visited subjects
on days 0, 1, 2, 4, 7, 14, 18, 21, and 28 after treatment was
initiated, to assess symptoms and to obtain blood specimens
for Giemsa smears. Unresolving or recurrent parasitemia dur-
ing the follow-up period prompted the administration of rescue
therapy with either sulfadoxine-pyrimethamine, quinine plus
doxycycline, or quinine alone, depending on the primary treat-
ment group and the clinical presentation. Any infection iden-
tified by routine screening after day 28 was considered to be a
new infection and was treated in accordance with the primary
treatment regimen assigned to that subject.
Treatment outcomes were assessed in accordance with the
most recent recommendations of the World Heath Organiza-
tion [15]. When outcomes could not be determined because
rescue therapy was administered too early to assess response
(when rescue treatment was provided on day 2 without a par-
asite density greater than that noted on day 0 of primary therapy
or when rescue therapy with a second agent was provided on
day 3 of follow-up without the parasite density exceeding 25%
of that on day 0 of primary therapy), they were excluded from
analysis. For actuarial (life table) estimates of the cumulative
incidence of treatment failure, subjects who were lost to follow-
up or who developed intercurrent infections with a new species
only contributed person-time to the point of the last blood
smear or the date of re-treatment, respectively.
All work was performed in accordance with code 32 of Fed-
eral Regulations Part 219 (Protection of Human Subjects) and
US Department of Defense, US Navy (SECNAVINST 3900
.39C), and Indonesian Ministry of Health guidelines for the
conduct of human use research. The protocols and informed
consent processes were reviewed and approved by convening
institutional review boards before research was initiated. Writ-
ten informed consent was obtained from all study subjects.
RESULTS
The characteristics of subjects in the 2 treatment arms were
similar (table 1). We treated a total of 1018 primary infections
during the 32-month study period, of which we could evaluate
975 (96%) (table 2). Forty-three chloroquine treatment courses
were excluded because rescue therapy was administered outside
of the set parasitological parameters. Species-specific parasite
densities among the 2 treatment groups were similar (table 2).
We observed no treatment-related serious or severe adverse
events in either cohort. Of the total number of infections di-
agnosed in the cohort during the study period, 9 were classified
by the treating physician as severe and were treated with qui-
nine. These treatment courses are therefore not included in this
analysis but are reported elsewhere [13]. In all 9 cases, the
patient recovered and resumed follow-up in the study, in ac-
cordance with the protocol. Intercurrent infections occurred
more frequently during follow-up in individuals treated with
chloroquine (relative risk [RR], 14; 95% CI, 4–64).
The overall 28-day mefloquine curative efficacy rates for P.
falciparum and P. vivax malaria were 96.4% and 99.6%, re-
spectively, compared with 26.2% and 81.6% among patients
treated with chloroquine. These differences were significant.
The RRs for treatment failure with chloroquine versus meflo-
quine were 20 (95% CI, 10–41) and 52 (95% CI, 7–376) for
P. falciparum and P. vivax, respectively. The early treatment
failure rates were relatively high in the chloroquine treatment
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Table 2. Characteristics and outcomes for 1018 patients with malaria in Papua, Indonesia, 1996–1999.
Variable
Plasmodium species, by treatment arm
Chloroquine Melfoquine
Pf Pv Pf/Pv Pf Pv Pf/Pv
No. of treatment courses 161 232 28 232 295 27
No. of intercurrent infection with different species 11 12 0 1 1 0
No. of losses to follow-up before day 28 1 8 3 10 11 1
No. of 28-day cures 39 173 11 213 282 23
No. of recurrences 110 39 14 8 1 3
Geometric mean parasite density at day 0,
parasites/mL (95% CI) 1757 (1362–2257) 799 (651–980) …a 1526 (1217–1913) 677 (569–804) …a
NOTE. A total of 464 treatments were administered in the chloroquine arm, and 554 were administered in the melfoquine arm. Forty-three and 0 patients
were excluded from the chloroquine and melfoquine arms, respectively, because rescue therapy was administered too early to determine outcome, leaving 421
and 554 evaluable treatment courses. Pf, Plasmodium falciparum; Pf/Pv, mixed P. falciparum and Plasmodium vivax; Pv, P. vivax.
a Included in single species columns.
arm for P. falciparum and P. vivax malaria (39% and 20%,
respectively). For mefloquine, only 1 early treatment failure for
P. falciparum malaria occur, and the single case of recurrent P.
vivax malaria after receipt of mefloquine treatment occurred
on day 28 and was classified as late treatment failure. Among
the treatment courses that we could evaluate, 56 (10%) of 554
and 117 (28%) of 421 of the total number of presumed new
infections in the mefloquine and chloroquine groups, respec-
tively, occurred 29–42 days after the initiation of therapy for
the previous infection. Taking into account the time contrib-
uted by each subject, the periodic cumulative incidences of
treatment failure are represented in figure 1.
Treatment outcomes in this cohort during the follow-up pe-
riod were not affected by age or number of documented prior
infections. The low number of treatment failures in the meflo-
quine group precluded analysis, but among subjects treated
with chloroquine, age group did not affect the risk of treatment
failure for P. falciparum malaria (RR, 1.15; 95% CI, 0.96–1.39)
or P. vivax malaria (RR, 1.15; 95% CI, 0.75–1.93). The number
of prior documented infections—a surrogate estimator of ex-
posure-related immunity—had no clear relationship with chlo-
roquine treatment outcome. Compared with first-infection
treatment outcomes, the RRs of treatment failure (stratified by
number of prior infections) were 1.31 (95% CI, 0.94–1.85) after
1 prior infection, 1.5 (95% CI, 1.08–2.09) after 2 prior infec-
tions, 1.39 (95% CI, 0.97–2) after 3 prior infections, and 1.1
(95% CI, 0.68–1.78) after 4 prior infections.
DISCUSSION
Chloroquine remains the first-line therapy for P. falciparum
and P. vivax malaria in Indonesia, except in some Ministry of
Health–designated areas where the combination of artesunate
plus amodiaquine has been approved for special use to assess
local efficacy, because combination therapies that contain ar-
temisinin are emerging as the treatments of choice for P. fal-
ciparum malaria internationally. Because increasing antimalarial
resistance impedes malaria-control efforts, new regimens are
required. We demonstrated high efficacy of mefloquine for ma-
laria in an area of eastern Indonesia where chloroquine is in-
effective against P. falciparum and chloroquine-resistant P. vivax
is well documented. In such areas where mefloquine-resistant
P. falciparum has not been documented, mefloquine may be a
suitable alternative treatment for either P. vivax or P. falciparum
malaria. In an era of waning proficiency in microscopic diag-
nosis of malaria, use of a single agent that covers both P. fal-
ciparum and P. vivax would reduce the risk of morbidity and
mortality associated with species misdiagnosis—specifically,
mistaking P. falciparum for another species and treating the
patient with an inferior regimen. The cost of mefloquine
($1.60–$4.85 [in US dollars] per treatment course) is compa-
rable to that for combination regimens like artesunate-
amodiaquine and artesunate-sulfadoxine/pyrimethamine [16],
and its single-dose regimen increases the likelihood of com-
pliance, compared with multiple-day regimens.
To our knowledge, the clinical efficacy of mefloquine against
chloroquine-resistant P. vivax has not been previously de-
scribed. The little data available on mefloquine therapy for P.
vivax malaria relates to efficacy against chloroquine-susceptible
P. vivax. Harinasuta et al. [3] compared the efficacy of a single
250 mg dose (4–6 mg/kg) of mefloquine with that of a single
450-mg dose of chloroquine in adult men with P. vivax malaria.
Chloroquine treatment failures did not occur, and the authors
attributed the 2 mefloquine treatment failures, occurring on
days 12 and 28 after the initiation of therapy, to inadequate
dosing. Both infections subsequently resolved after re-treatment
with chloroquine. A study from Thailand [4] compared the
efficacy of a single 1500-mg dose of mefloquine in 15 adults
with P. vivax malaria with a 1500-mg dose of chloroquine, with
or without primaquine, given over the course of 3 days to 25
adults with P. vivax malaria; it revealed 28-day cure rates of
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Figure 1. Cumulative incidence of therapeutic failure (CIF) among 975 treatment courses of chloroquine or mefloquine for uncomplicated Plasmodium
falciparum or Plasmodium vivax malaria in Papua, Indonesia, 1996–1999. CQPf, chloroquine treatment for P. falciparum malaria; CQPv, chloroquine
treatment for P. vivax malaria; MQPf, mefloquine treatment for P. falciparum malaria; MQPv, mefloquine treatment for P. vivax malaria.
100% in all groups. A more recent study from Thailand, where
chloroquine remains effective against P. vivax, reported recur-
rent parasitemia in 2 of 17 mefloquine-treated patients (15 mg
base/kg) and 1 of 21 chloroquine-treated patients (25 mg base/
kg) cases only after day 28 [6].
Late, recurrent P. vivax parasitemia is generally attributed to
either reinfection or, more commonly, relapse of Asian strains,
as levels of slowly eliminated antimalarials like chloroquine and
mefloquine decrease to less than the level required to suppress
emergence of blood-stage parasites [17]. We observed an 18%
rate of recurrent P. vivax parasitemia before day 28 among
individuals who were treated with chloroquine plus prima-
quine, but there was only 1 instance of recurrent P. vivax par-
asitemia in the mefloquine plus primaquine group (on day 28).
In this study, the 28-day rate of chloroquine treatment failure
for P. vivax was much lower than was previously reported from
this region (71%–78%) [12, 18]. We combined primaquine
with chloroquine, a combination previously shown to improve
28-day cure rates for P. vivax malaria over chloroquine alone
(85% vs. 22%) [18]—a finding that was not observed when
therapeutic doses of primaquine are combined with chloro-
quine to treat chloroquine-resistant P. falciparum malaria, for
which relapse does not occur [19]. These data suggest that
previous methods for assessing treatment outcomes for blood-
stage P. vivax infection, which did not control for relapse
through administration of primaquine to cure hypnozoite
stages, overestimate true recrudescence (i.e., blood-stage treat-
ment failure) rates. Although we administered primaquine (15-
mg base) to all subjects with P. vivax malaria, much higher
doses are now recommended for strains from New Guinea,
which appear to be tolerant of the standard 15-mg/kg dose that
is generally recommended and that was used in this study [17].
Similarly, the higher degree of intercurrent infections with both
P. vivax and P. falciparum observed in the chloroquine group,
compared with the mefloquine group, illustrate the persistent
blood-stage chemosuppressive effects of these agents, with me-
floquine being far superior at suppressing recrudescence, re-
lapse, and/or reinfection with P. vivax through day 28.
After careful review of the literature, we identified no clear
evidence of the occurrence of mefloquine-resistant P. vivax [7–
9]. Amor and Richards [7] reported the occurrence of P. vivax
infection in an adult who was taking mefloquine prophylaxis
while living in Papua, New Guinea. However, compliance with
treatment was not confirmed, and blood concentrations of the
drug were not measured to document adequacy of the level at
the time of infection. Similarly, a reported case in India of
mefloquine treatment failure on day 13 of treatment was based
on the finding of 1 ring and 1 trophozoite on the thick smear
that was not confirmed by thin smear, repeated thick smears,
immunochromtography, or PCR [9]. Alecrim and colleagues
report the most compelling evidence for mefloquine resistance
in P. vivax in an adolescent female subject, who, after chlo-
roquine therapy failed, was given mefloquine (20 mg/kg) on 2
occasions and who developed recurrent parasitemia [8]. Again,
the possibilities of malabsorption and inadequate blood con-
centrations were not explored.
Individuals with P. falciparum malaria who received meflo-
quine had a 20-fold lower risk of recurrent parasitemia during
the 28-day follow-up period, compared with those treated with
chloroquine. Determining the appropriate follow-up period
necessary to accurately estimate malaria treatment cure rates is
often complicated by the risk of reinfection in locations where
malaria is endemic. Many experts suggest that at least 42–63
days of follow-up is necessary to adequately assess therapeutic
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responses to mefloquine [20]. Among patients treated with
mefloquine and monitored in locations in Thailand where ma-
laria is presumed to be nonendemic, 17%–50% of P. falciparum
recrudescences occurred between days 28 and 42 after therapy
[21]. Our study was conducted in an area of Papua where
malaria is endemic and where malaria incidence rates were
estimated as high as 3.2 cases per person-year [13]. Therefore,
a risk of reinfection between days 28 and 42 of follow-up did
exist. As observed in our study, 10% and 28% of presumed
new P. falciparum infections in the mefloquine and chloroquine
treatment groups, respectively, occurred during that window.
Some of these infections are likely recrudescences. Although
genotyping of the merozoite surface protein 2 gene has been
established as a useful tool for distinguishing recrudescence
from reinfection [22], and although the World Health Orga-
nization has recently advocated its use for this purpose [20],
this technology was not available at our laboratory during the
execution of this study. However, because we identified infec-
tions between days 28 and 42 after treatment of a prior infection
as “new” in both groups and more commonly in the chloro-
quine group, we believe that this study still validates meflo-
quine’s superiority over chloroquine, and we advocate use of
this agent in the region as an efficacious alternative therapy for
both P. falciparum and P. vivax malaria.
Finally, this study also provided the opportunity to examine
the impact of immunity on clearance of parasitemia and clinical
cure in the face of ineffective chloroquine therapy. In malaria,
the role for immunity in clearing infection has been established
[23]. Although age is frequently considered to be a surrogate
marker of exposure-related immunity in locations where ma-
laria is endemic, we observed no differences between adults
and children in outcomes after chloroquine treatment for P.
falciparum and P. vivax. However, in this cohort, both adults
and children had no malaria exposure histories before initiation
of the study. Still, despite evidence of clinical immunity (man-
ifested by the lack of fever), by the fourth infection after arrival
of this cohort in Papua [14], we observed no increase in chlo-
roquine cure rates among individuals with increasing numbers
of infections. However, very few individuals in this study had
15 infections during the course of the 3-year study, rendering
statistically significant analysis of the impact of higher numbers
of prior infections on chloroquine treatment outcome not
possible.
This report constitutes the first published evidence, to our
knowledge, from a large-scale clinical trial of the efficacy of a
standard 15 mg/kg dose of mefloquine against chloroquine-
resistant P. vivax. Although this study was completed 5 years
ago, we do not anticipate emergence of mefloquine resistance
during the intervening period, because mefloquine has not been
available in Indonesia and, therefore, is not a factor in the
development of selective resistance in Indonesian Papua. When
used in malaria-endemic locations, it can provide the added
benefit of short-term prophylaxis against chloroquine-resistant
strains of P. falciparum and P. vivax. In areas where mefloquine-
resistant P. falciparum does not occur, mefloquine provides an
alternative for treating malaria, particularly when species de-
termination at the local level may not be possible.
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